

F. RANCÉ<sup>1</sup>\*, A. DESCHILDRE<sup>2</sup>\*, F. VILLARD-TRUC<sup>3</sup>, S.A. GOMEZ<sup>3</sup>, E. PATY<sup>4</sup>, C. SANTOS<sup>2</sup>, L. COUDERC<sup>5</sup>, J.L. FAUQUERT<sup>6</sup>, J. DE BLIC<sup>4</sup>, E. BIDAT<sup>7</sup>, C. DUPONT<sup>8</sup>, P. EIGENMANN<sup>9</sup>, G. LACK<sup>10</sup>, P. SCHEINMANN<sup>4</sup>, SFAIC AND SP2A WORKGROUP ON OFC IN CHILDREN\*\*

## Oral food challenge in children: an expert review

Position paper of the Section of Pediatrics of the French Society of Allergology and Clinical Immunology (SFAIC) and of the Pediatric Society of Pulmonology and Allergology (SP2A)

<sup>1</sup>Allergologie – Pneumologie, Hôpital des Enfants, Toulouse, France; <sup>2</sup>Unité de Pneumologie et Allergologie Pédiatriques, Clinique de Pédiatrie, Hôpital Jeanne de Flandre, Lille, France; <sup>3</sup>Service de Pneumologie et Allergologie Pédiatriques, Hôpital Debrousse, Lyon, France; <sup>4</sup>Service de Pneumologie et Allergologie Pédiatriques, Hôpital Necker-Enfants-Malades, Paris, France; <sup>5</sup>Unité de Pneumologie et Allergologie Pédiatriques, Hôpital Charles-Nicolas, Rouen, France; <sup>6</sup>Unité d'Allergologie de l'Enfant, Hôtel Dieu CHU, Clermont-Ferrand, France; <sup>7</sup>Service de Pédiatrie, Hôpital Ambroise Paré, Boulogne, France; <sup>8</sup>Département de Néonatalogie et Gastroentérologie Pédiatrique, Université René Descartes, Paris, France; <sup>9</sup>Allergologie Pédiatrique, Hôpital des Enfants, Geneva, Switzerland; <sup>10</sup>Paediatric Allergy, Evelina Children's Hospital, Guy's & St Thomas' Hospitals NHS Foundation Trust, King's College, London

### KEY WORDS

*Oral food challenge, food allergy, child, skin prick test, atopy patch test, specific IgE determination, adrenaline, GRADE evidence*

### SUMMARY

*Oral food challenges are indicated for the diagnosis of food allergy and the double-blind, placebo-controlled oral food challenge is considered the gold standard diagnostic method in children with suspected food allergy. This practice parameter for oral food challenges in children was prepared by a workgroup at the request of the French Society for Allergology and Clinical Immunology (SFAIC) and the French Paediatric Society for Allergology and Pulmonology (SP2A). We aimed to develop practical guidelines for oral food challenges in children for the diagnosis of suspected food allergy or the evaluation of food tolerance. We also considered the safety measures to be implemented during testing and management of the potentially serious allergic reactions that may arise during the test. The strength of the recommendations was established, using the GRADE evidence-based approach. We considered four issues: 1) the selection of children for oral food challenges (indications and contraindications); 2) the procedure used (material, where the test should be carried out, technique and management of reactions); 3) interpretation of the test and 4) consequences of the test.*

**Abbreviations:** FA, food allergy; OFC, oral food challenge; DBPCFC, double-blind placebo-controlled food challenge

\* F. Rancé and A. Deschildre contributed equally to this work;

\*\* Workgroup contributors: Castelain C, Marguet C, Le Pabic F, Sabouraud D.

## Introduction

The frequency of food allergies (FAs) is currently estimated at around 5% of the paediatric general population (1, 2). FAs in children may be life-threatening (3, 4) and have become both a major public health problem and a source of concern to many healthcare professionals. Treatment is based on avoidance, which may be difficult to achieve given the high frequency of masked allergens (5). Children may grow out of some FAs, whereas others may persist and alter quality of life. FAs have particularly important repercussions for children of school age (6, 7).

The correct diagnosis of FAs on the basis of reliable criteria is therefore essential, together with follow-up of their progression. This requires a combination of skin tests (skin prick tests and atopy patch tests in some cases), specific IgE determinations and oral food challenges (OFCs) (1, 8). There is currently a trend towards the development of screening tests for FA diagnosis, reducing the indications for OFCs. This approach has resulted in the establishment of threshold values for skin tests and specific IgE predicting the likelihood of a clinical reaction (9-18). However, threshold values have not been established for all foods, and they depend on the food considered, the study population, the age of the child at the time of diagnosis and the symptoms (19). Thus, in practice, with the exception of certain well defined situations, OFCs are still frequently indicated, and the double-blind placebo-controlled food challenge (DBPCFC) is the gold standard for FA diagnosis (5, 8).

In OFCs, the subject is asked to ingest the food tested, with the aim of reproducing the symptoms, taking into account the time and the quantity of the food required to generate symptoms. OFCs can be used to evaluate the amount of a food required to trigger symptoms (expressed as a cumulative reactogenic dose, eliciting dose or as the dose triggering symptoms) and the nature of clinical signs related to ingestion of the suspected food. Indications for this test are now better known (20-25). However, no global recommendations developed from a literature review have ever been published concerning the indications, consequences and safety measures relating to OFCs or the management of allergic reactions arising during these tests.

This document is an expert review, prepared by a workgroup at the request of the French Society for Allergology and Clinical Immunology (SFAIC) and the French Paediatric Society for Allergology and Pulmonology (SP2A). We aimed to build a practice parameter and to formulate

recommendations specifying the indications, procedure and consequences of OFCs in children. We considered four major issues: 1) the selection of children for OFC (indications and contraindications); 2) the complete procedure which should be followed (material, where the test should be carried out, technique and management of reactions); 3) the interpretation of the OFC and 4) the consequences of the OFC. These recommendations focus in particular on the three major foods most frequently implicated in FA in children: cow's milk, hen's eggs and peanut. OFCs are carried out similarly for other foods and these recommendations could therefore be applied to other foods. These recommendations concern paediatric tests, and are aimed at physicians involved in the management of FA in children.

We carried out a literature review, based on studies published between 1971 and 2007 identified by querying the PubMed® database. The search was limited to studies published in English or French. Some articles were also identified from the bibliographic references cited in the articles identified by the PubMed® query. In this analysis, priority was given to systematic reviews, studies of cohorts of allergic children and recommendations issued by scientific societies. The working draft of this practice parameter was reviewed by a large number of experts on FA. The working draft concerning each issue was published in French (26-31). This document represents an evidence-based and broadly accepted synthesis and consensus viewpoint of the working group on OFC for FA in children. The strength of the recommendations and the quality of the evidence were defined according to the GRADE evidence-based approach (Tab. 1) (32).

### I. What are the indications and contraindications for OFC?

The main indication for OFC is testing whether a child is allergic to the food suspected (grade 1A). The indications for OFC are: (i) testing whether a child is allergic or tolerant to a particular food and (ii) determining whether a child has grown out of the FA and whether the food can safely be reintroduced into the diet. Indications for OFC should also take into account the food concerned (nutritional value, difficulties with avoidance), signs associated with the FA, the age of the child, the course of the allergy and the constraints imposed by the FA (19-25).

The clinical situations analysed included both immediate (generally within two hours, more rarely within four

**Table 1** - Grading recommendations according to the GRADE working group (32)

Grade of recommendation	Benefit vs risk and burdens	Methodological quality of supporting evidence	Implications
1A: strong recommendation, high-quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	RCTs without important limitations or overwhelming evidence from observational studies	Strong recommendation, can apply to most patients in most circumstances without reservation
1B: strong recommendation, moderate quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	RCTs with important limitations (inconsistent results, methodological flaws, indirect, or imprecise) or exceptionally strong evidence from observational studies	Strong recommendation, can apply to most patients in most circumstances without reservation
1C: strong recommendation, low-quality or very low-quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	Observational studies or case series	Strong recommendation, but may change when higher quality evidence becomes available
2A: weak recommendation, high-quality evidence	Benefits closely balanced against risk and burdens	RCTs without important limitations or overwhelming evidence from observational studies	Weak recommendation; best action may differ depending on circumstances or patients' or societal values
2B: weak recommendation, moderate-quality evidence	Benefits closely balanced against risk and burdens	RCTs with important limitations (inconsistent results, methodological flaws, indirect, or imprecise) or exceptionally strong evidence from observational studies	Weak recommendations; best action may differ depending on circumstances or patients' or societal values
2C: weak recommendation, low-quality or very low-quality evidence	Uncertainty in the estimates of benefits, risk, and burden; benefits, risk, and burden may be closely balanced	Observational studies or case series	Very weak recommendations; other alternatives may be equally reasonable

hours of ingestion) and delayed (atopic eczema, gastrointestinal food-induced allergic disorders) manifestations and sensitisation to a food that the child had never consumed.

## 1.1 Diagnosis of FA

### 1.1.1 General aspects

Clinical history, skin tests (skin prick tests and atopy patch tests) and specific IgE (ImmunoCap, Phadia, Uppsala, Sweden) determinations may lead to OFCs (grade 1A). History checks the time at which occur the symp-

toms, the relationship with any feeding, and clinical features. OFC is not indicated in children with a clinical history suggestive of allergy and positive results in skin tests or specific IgE (5) (grade 1A). The clinical history is considered suggestive of allergy if associated with an IgE-dependent mechanism – if cutaneous signs (eczema, rash, urticaria, angioedema), gastrointestinal signs (nausea, vomiting, diarrhoea, abdominal pain), respiratory signs (rhinoconjunctivitis, cough, respiratory distress, bronchospasm) and/or arterial hypotension occur shortly after ingesting the food. Anaphylaxis is a life-threatening event, but may also be defined as the occurrence of clinical signs affecting at least two organs (3, 4).

OFC is indicated if clinical history is not considered sufficiently convincing – if the symptoms reported are imprecise and/or do not seem to be markedly associated with consumption of the food concerned, particularly in cases of atopic eczema.


### I.1.2 Indication for OFC in cases of suspected IgE-dependent FA

The indication for OFC in cases of suspected IgE-dependent FA is based on decision point values for skin prick tests and food-specific IgE tests (ImmunoCap, Phadia, Uppsala, Sweden), when such values exist (Fig. 1). However, decision points may vary with the method, extract, foods involved, and features of the population, such as age and disorders considered (24, 33, 34). Negative results in prick tests using a commercial extract should lead to control with the natural food (16, 35-37) (grade 1B).

**Peanut:** The decision points established for peanut are a weal of at least 8 mm diameter in children over the age of two years and of at least 4 mm in children under the age of two years in skin prick tests with commercial extracts, or a specific IgE concentration of at least 14 kIU/l (ImmunoCap, Phadia, Uppsala, Sweden) (13-15, 38, 39) (grade 1C).

**Cow milk:** The decision points established for cow's milk are a weal of at least 8 mm diameter in children over the age of two years and of at least 6 mm in children under the age of two years, in skin prick tests with commercial extracts, which are no longer available in certain countries (including France) (15) (grade 1C). It is currently not possible to calculate a decision point for specific IgE levels for cow's milk from published data (11-13, 17). The decision point varies according to age group and the prevalence of FA and atopic eczema in the population studied. Garcia-Ara et al. obtained a threshold level of 2.5 kIU/L with a positive predictive value (PPV) of 90% (mean age of 6.5 months, FA prevalence 44%) (11). In the study by Roehr et al., the threshold level was 17.5 kIU/L, with a PPV of 86%, for a population with a mean age of 13 months and an FA prevalence of 55% (12). In the prospective study by Sampson and Ho (13), a threshold level of 32 kIU/L with a PPV of 95% identified in a retrospective study (9) led to an OFC being carried out in 34% of cases. The mean age of the patients was 3.8 years and the prevalence of FA was 66%. Celik-Bilgili et al. reported a threshold level of 88.8 kIU/L, with a PPV of 90%, in a population with a mean age of 13 months and an FA prevalence of 49% (17).

**Figure 1** - Diagnostic procedure for children with suspected IgE-dependent food allergy (cow's milk, hen's eggs, peanut)



*Hen's egg:* The decision points established for hen's egg are a weal of at least 7 mm in children over the age of two years and of at least 5 mm in children under the age of two years, in skin prick tests with commercial extracts (egg white) or a specific IgE concentration of at least 7 kIU/l (2 kIU before the age of 2 years) (egg white, ImmunoCap, Phadia, Uppsala, Sweden) (10, 13-16) (grade 1C).

### 1.1.3 Indication for OFC in cases of suspected delayed reaction


In cases of delayed reactions, eczema or gastrointestinal disorders, OFC is indicated if an avoidance diet for the food identified in allergy testing (skin prick tests, specific IgE, atopy patch test) and/or food diaries – maintained over four weeks, or possibly longer for gastrointestinal symptoms, according to the EAACI position paper – proves to be effective, particularly for gastrointestinal symptoms (Fig. 2) (5, 18, 25, 33, 40-44) (grade 1C). If an improvement is observed, the timing of an OFC should be discussed, on a case-by-case basis, in specialist consultations.

Atopy patch tests can be useful as an additional diagnostic tool, following negative prick test and undetectable specific IgE, in cases of delayed reactions, particularly to cow's milk (18, 44-47) (grade 2B). However, a recent evaluation of children with atopic eczema suggested that the need for OFC was not significantly lower in cases of suspected food-induced eczema (18). Additional studies are required to resolve this issue. Standardized atopy patch tests could be useful in the diagnostic work-up for children with gastrointestinal symptoms (41, 42) (grade 2C).

### 1.1.4 Indication for OFC in cases of sensitisation to foods never consumed

In children sensitised to foods that they have never consumed, and in documented cases of sensitisation or suspected cross-reaction between food allergens (Fig. 3), the indications for an avoidance diet or OFC depend on the food concerned, the age of the child and the results of allergological tests, according to specialist advice (grade 2A). If an avoidance diet is prescribed, allergological assessment should subsequently be repeated (grade 2C). When testing for cross-reactions, a negative skin prick test with the food in its native state rules out allergy to that food. If the skin prick test is positive and the child has never consumed the food, the possibility of carrying

**Figure 2** - Diagnostic procedure for children with delayed signs (eczema, gastrointestinal signs)



out an OFC should be discussed during a specialist consultation (33) (grade 2B).


### 1.2 Evaluation of the eliciting dose

OFC can be used to determine the amount of a food required to trigger symptoms (expressed as the *eliciting dose* or *cumulative reactogenic dose*). Determination of this dose alone is not an indication for OFC in clinical practice, because it may be affected by several factors such as fat content, may change over time, or may be different in real life (48-51) (grade 1C).

### 1.3 Evaluation of tolerance to a food

The aim is to define indications for OFC in children with a known FA, when the natural history of this allergy is naturally progressing towards possible resolution. Tolerance to cow's milk and hen's eggs is frequently acquired, but is rarer for peanut (1, 52-56) (grade 1C). Tolerance is rarely acquired after the age of five to seven years and is almost never acquired after the age of 12 years (4, 57-59)

**Figure 3** - Diagnostic procedure for children sensitised to a food that they have never consumed



(grade 1C). For this indication, the OFC is sometimes referred to as a *reintroduction test*. Before OFC, it is important to obtain agreement with regular food consumption in case of negative food challenge (60) (grade 1C).

The skin prick test weal diameter and/or specific IgE level values considered significant for the acquisition of oral tolerance depend on the food considered, the age of the child and the nature of the initial clinical reaction. An analysis of intra-individual variations in specific IgE levels may be useful (33, 61-65). In individuals, OFC may be considered when serum food-specific IgE levels decrease to a range at which about 50% of children of the corresponding age tolerate the food concerned, e.g. < 2 kIU/l for hen's eggs (white), < 2 kIU/l for cow's milk, < 5 kIU/l for peanut with an uncertain medical history of allergy or < 2 kIU/l if there is a clear history of allergic reactions (ImmunoCap, Phadia, Uppsala, Sweden) (33, 64).

Finally, the decision to carry out an OFC depends on medical history, current age of the patient, age at which

the FA considered is most frequently cured (1 year for cow's milk, 3 years for hen's eggs and 6 years for peanut), and repeated test results (grade 1C).

#### 1.4 Exclusion criteria for OFC

The appropriate selection of indications for OFC should limit the risk of severe reactions. The size of the weal in skin prick tests and specific IgE concentrations are not predictive of the severity of the clinical reaction or of the minimal dose required to trigger symptoms (62, 66) (grade 1C). OFC is rarely performed in infants under the age of 6 months. Nevertheless, age is not a contraindication. The pollen production season may modify the outcome of challenge tests for fruits and vegetables associated with an oral allergy syndrome and cross-reaction to pollen. Nevertheless, season is not a contraindication for fruit and vegetable challenge in cases of oral allergy syndrome.

Exclusion criteria for OFC include (20-25) (grade 1C):

- Active chronic disease
- Poorly controlled asthma or FEV<sub>1</sub> below 80% of the predicted value
- Recent anaphylactic reaction to a food, with consistent allergological test results
- Absence of consent
- Relative contraindication: treatment which may mask or delay clinical reactions or may interfere with the treatment of such reactions (beta blockers, aspirin and non-steroidal anti-inflammatory drugs, ACE inhibitors).

## II. In what environment and what conditions should OFC be carried out?

### II.1 Where should the OFC be carried out?

The OFC should be carried out in hospital environment with facilities for managing severe allergic reactions, geographically close to an intensive care unit with medical and paramedical staff experienced in performing the procedure. The test should be carried out in appropriate conditions, with the necessary level of safety, monitoring and evaluation. The prior information of patients and their families and the obtainment of informed consent are essential for OFCs. The nurses involved must therefore have experience of both carrying out the test and monitoring reactions to the test and a doctor must be present on the site (8, 24, 25, 67) (grade 1B). Any site at which OFCs are carried out should have monitoring facilities, and the drugs and mate-

rials required for resuscitation, to ensure that reactions can be treated appropriately, regardless of their severity or the age of the child (8) (grade 1B). Before beginning the test, the doctor responsible for monitoring should write a protocol for the treatment of adverse reactions.

Day hospital admission may be sufficient. However, monitoring for at least four hours after administration of the last dose is recommended, to cover the period in which immediate severe reactions may occur and for the diagnosis of certain delayed reactions. The occurrence of a reaction may lead to hospitalisation for observation. For delayed symptoms, such as eczema, the OFC should be started in a hospital environment, but extended challenges may then be continued outside the hospital. It may be relevant to complete the test at the hospital or to ask the patient to return for evaluation if symptoms occur (or to take pictures or videos).

## **II.2 Preparation of the foods used for OFCs**

The allergenicity of foods may depend on their presentation (48, 49) (grade 1B). In practice, it is recommended to test the food in the form consumed by the patient (roasted peanuts, for example). For foods consumed in several forms, the choice depends on the indication for OFC (e.g. raw egg, cooked egg) (68). The use of lyophilized food in capsules is not recommended in children, because oral allergy syndrome can be overlooked and the dose may not be high enough.

In open testing, the vehicle used should render the food acceptable to the child. In blind testing, the vehicle is used to disguise the taste of the food. There are currently no standardised, validated consensual recommendations. A recent study indicated inherent difficulties in this procedure (69). A non-suspect food can be used to mask the test food and as a placebo. The preparation to be tested and the placebo must have similar tastes, appearances, odours, textures and volumes (69, 70). The food should be present in the vehicle at the highest concentration possible at which it remains undetectable. All ingredients likely to provoke undesirable reactions should be avoided. The vehicle should have a low fat content, particularly for peanut challenges (49). Paste-like vehicles, such as mashed potato and apple compote, are the most frequently used, but liquid vehicles are also possible. Liquid foods can be masked in extensive hydrolysates of cow's milk, or in amino acid-based formulas. A dietician or pharmacist may have a useful input in the development of recipes and reintroduction protocols.

## **II.3 The patient**

### *II.3.1 Diet*

The food tested should, in all cases, have already been eliminated from the child's diet. The main purpose of the diet is to ensure that the patient is symptom-free or as close to symptom-free as possible, for diagnostic OFC and its evaluation. The food concerned should therefore have been avoided for at least seven to 14 days (depending on the food) for immediate reactions and at least four to six weeks for delayed reactions (25, 43) (grade 1C). For children who are still breast-feeding, the suspect food should be eliminated from the mother's diet (23). A dietician may be required to control the nutritional aspects of an avoidance diet.

### *II.3.2 Clinical state and maintenance treatment*

The OFC should be carried out in conditions of clinical stability, in the absence of other signs (e.g. infections) likely to make interpretation difficult. In cases of atopic dermatitis, the OFC should be carried out on patients with minimal treatment or no local treatment (25, 71) (grade 1C). In the case of patients with co-existing or food-induced asthma, short-acting inhaled agonists and inhaled anticholinergics may be continued up to four and six hours before challenge, respectively. Maintenance treatments for asthma should be continued, even on the day of the test (24, 72) (grade 1C).

Some treatments that may modify the result of the test should be stopped at various times before the OFC. Leukotriene receptor antagonists should be withheld for up to one week, antihistamines for a minimum of 48 hours (hydroxyzine should be stopped 72 hours before the test and latest-generation antihistamines should be withheld for at least one week) (22). Other maintenance treatments, such as neuroleptics, oral corticosteroids and immunosuppressors, are not compatible with OFC (24) (grade 1C).

### *II.3.3 Should the OFC be carried out in the fasting state?*

The child should have fasted for at least two hours before the OFC, to prevent any interference with the food tested (immediate reaction) and to prevent the occurrence of clinical signs attributable to fasting and making interpretation of the test difficult. During the OFC, the medical staff may allow the child to eat certain foods with no risk of reaction. Water and apple juice are authorised.

### II.3.4 Should an intravenous catheter be implanted?

The insertion of an intravenous catheter before the OFC is recommended, due to the unpredictable and sometimes serious reactions observed and the possible requirement for treatments administered intravenously (24) (grade 1C). However, this measure is not indispensable and should be considered on a case-by-case basis, as a function of clinical history, age, allergic background, the food concerned and the results of allergy testing (73).

### II.3.5 Clinical evaluation before the test

A clinical evaluation should be carried out before the OFC. The results and monitoring parameters should be reported on a monitoring sheet, dated and signed by the doctor, authorising or prohibiting the OFC, according to the state of the child (74).

## III. What procedures should be used when carrying out an OFC?

### III.1 Types of challenge

OFCs can be carried out in open, single-blind or double-blind procedures. First-line tests in children are carried out in open conditions, particularly when searching for objective signs in a young child (8) (grade 1C). *For open challenge tests*, the food is given in its natural form. *For single-blind tests*, the food (or placebo) is given in a vehicle that disguises the appearance and the taste of the food. The child is unaware of the nature of the food given (test food or placebo), whereas the doctor, nurses and parents have this information. *For double-blind, placebo-controlled tests*, none of the parties involved (patient, doctor, nurses, family) is aware of the composition of the product delivered to the child. The double-blind method is the preferred method for scientific research protocols. DBPCFC is considered to be the gold standard (24). DBPCFCs are particularly recommended for studies of delayed reactions (e.g. eczema) and in cases of a particular psychological context or of subjective symptoms (e.g. abdominal pain in older children) (33). It is always followed by the ingestion of the food in its usual quantity, in open conditions, with monitoring (75) (grade 1B). The interpretation of DBPCFCs is summarised in table 2. In infants and young children, open controlled OFC are sufficient for FA diagnosis (24).

**Table 2** - Interpretation of double-blind, placebo-controlled oral food challenge

Food	Placebo	Recommandation
+	-	Avoidance diet
+	+	Repeat the test
-	-	No diet
-	+	No diet

### III.2 Dosing

The food is given in incremental doses, beginning with an initial dose of 1 mg (possibly even less) to 250 mg (protein content), depending on the indications. The lowest doses are used for subjects with a history of severe reactions. Reference to natural foods or food proteins may be used and this choice should be defined in advance. Reference to protein content is preferable, but it should be specified whether the weight of the natural food is used for the challenge. The OFC may be preceded by a labial challenge test (76) (grade 2B). However, some children may have contact reactions during labial challenge despite tolerating oral intake.

Incremental doses are delivered every 15 to 30 minutes (24). In the absence of clinical signs, the highest dose administered should correspond to the normal daily intake for children of the corresponding age (24). There is no standardised protocol. Various incremental protocols are available and the choice depends on the clinical history of the subject. In patients with delayed symptoms, the OFC is carried out over several days, and the monitoring procedure focuses on delayed symptoms (25, 40). Certain clinical situations require particular procedures. This is the case for exercise anaphylaxis, in which the OFC must be combined with physical exercise. There is no validated procedure for tests of this type.

In DBPCFCs, the placebo is given in the same incremental manner, on another day, chosen at random (20, 21, 24, 25) (grade 1B). It is also possible to integrate ingestion of the placebo into the progression (51). Finally, the OFC may be carried out over several days, alternating ingestion of the test food and of the placebo. This procedure is particularly useful for delayed or subjective signs (24).

### III.3 Specific features linked to the food

As a rule, the total dose should correspond to a normal daily intake (20-22, 23-25) (grade 1B). For peanut, OFCs



with cumulative doses of at least 8 g (1 peanut weighs about 600 mg) can be carried out. For cow's milk, progressive increases for OFCs are measured in ml (1 to 250 ml). The dose of milk administered should be adapted according to the age of the subject. The milk generally consumed by the child should be used. OFCs for hen's eggs can be carried out with raw or cooked egg, with the total amount corresponding to the equivalent of one egg. For OFCs with raw egg, the use of a low initial dose is recommended. A negative result for OFC with cooked egg shows that the child tolerates cooked egg, but provides no information about the tolerance of raw egg (68).

The progressive increases used for OFCs with other foods are highly variable. The initial dose takes into account the severity of symptoms already presented, or the food (e.g. low initial dose for fish, shellfish, and sesame). The final dose may be high (e.g. for wheat).

#### **IV. How should allergic reactions occurring during OFCs be managed?**

The clinical symptoms likely to occur during food OFCs range from benign signs (often cutaneous) to more serious respiratory and/or cardiovascular signs. It is important to bear in mind the possibility of anaphylactic reaction. H1 antihistamines may mask the early signs of anaphylaxis. Recognition of the initial symptoms, followed by the treatment of these symptoms, may prevent progression to more serious clinical situations (22) (grade 1C). Patients with persistent asthma have the highest risk of anaphylaxis.

##### ***IV.1 Drugs***

Adrenaline is the first-line treatment for anaphylaxis (3, 4, 67) (grade 1A). There is no contraindication for its use in paediatrics. Delayed injection is associated with a poor prognosis. Adrenaline should be administered by intramuscular injection into the thigh (lateral flank), rather than subcutaneously or intravenously (risk of arrhythmia). The dose is 0.01 mg/kg (maximum of 0.5 mg by injection) (77). Injections may be repeated every five to 10 minutes, or even more frequently, if the symptoms persist or worsen. Intravenous injection should be carried out only in cases of cardiac arrest and requires monitoring in an intensive care unit (3, 4, 67) (grade 1B).

The others options for treating acute allergic symptoms are based on H1 antihistamines, beta-agonist bronchodilators, and corticosteroids (3, 4, 67).

H1 antihistamines are indicated for the treatment of benign allergic manifestations, such as urticaria, angio-oedema, rhinoconjunctivitis and isolated abdominal pain (78, 79). They are not sufficiently effective to control severe allergic reactions (anaphylaxis, laryngeal oedema) and should not delay adrenaline injection (3, 4, 67) (grade 1A). Short-acting beta-agonists are administered by inhalation and are indicated in cases of isolated asthma attacks provoked by testing (80) (grade 1A). They are administered via a spacer device or nebuliser, depending on the severity of the symptoms. The dose is four to 15 puffs with a spacer device, or one to two puffs/kg (maximum 20 puffs), to be repeated, if necessary, every 10 to 20 minutes (81). The dose used with a nebuliser is 2.5 mg for children weighing less than 16 kg and 5 mg for children weighing more than 16 kg, in salbutamol equivalents, to be repeated every 20 minutes if necessary (82).

Steroids have little or no immediate effect, generally exerting their effects about four to six hours after administration (grade 1B). They should not be used as a first-line treatment for anaphylaxis. These drugs may be indicated in patients with a history of asthma (3, 4, 67) (grade 2C). Oral steroids are administered at a dose of 1 to 2 mg/kg prednisone or prednisolone (maximum 60 mg), and intravenous steroids at a dose equivalent to 1 to 2 mg/kg methylprednisolone.


Other measures include oxygen treatment in cases of asthma or shock (3, 4, 67) (grade 1A). The patient should be placed in a recumbent position with the lower extremities elevated. The administration of a crystalloid-containing (normal saline) or colloid-containing solution at a dose of 20 ml/kg over 10 to 15 minutes, repeating this treatment as necessary, is indicated in cases of hypotension or collapse (grade 1B). In cases of hypotension not responding to adrenaline or crystalloid solution (volume > 40 ml/kg), vasopressor treatment (noradrenaline, vasopressin) should also be given (67) (grade 1B).

##### ***IV.2 Indications***

Therapeutic management depends on the severity of the clinical symptoms (Fig. 4).

- 1) Intramuscular adrenaline injection is the first-line treatment for anaphylaxis, laryngeal oedema, collapse or a combination of these symptoms, and for rapid progression of symptoms (2) (grade 1A). The prognosis depends on the rapidity of diagnosis and adrenaline administration (2) (grade 1B).
- 2) Adrenaline is indicated in cases of asthma attack resistant to short-acting beta-agonists (2) (grade 1A).

**Figure 4** - Treatment of allergic reactions occurring during OFC in children



- 3) In cases of benign or mild reactions, a history of asthma or severe reaction to the food should lead to the administration of antihistamines and oral corticosteroids (grade 2C).
- 4) All severe reactions, particularly those requiring adrenaline injection, should be followed by monitoring at the hospital, taking into account descriptions of the biphasic reactions that may occur over a 24-hour period (3, 4) (grade 1C).

## V. How should the OFC be interpreted?

### V.1 Criteria

The criteria for OFC interpretation take into account the characteristics of the child (medical history, selection criteria for OFC, food tested, duration of monitoring) and the OFC technique used (open or blind) (24) (grade 2B). A single objective criterion is sufficient to define an OFC as positive, confirming FA. The identification of an isolated subjective sign leads to continuation of the test, with

intensive monitoring, in the hope of identifying a secondary objective sign, a switch to blind OFC, or to the test being stopped.

A negative OFC result may be used to confirm the absence or development of tolerance to FA (24) (grade 1A). The OFC may be considered negative if no immediate or delayed reactions are observed (25). In cases of uncompleted OFCs, a lack of reaction provides conclusive information concerning only the dose and form of the food tolerated.

In some cases, the OFC cannot be interpreted and must be repeated in a different manner.

Finally, “false negative” outcomes of OFC are reported. This may be the result of the loss of relevant allergen proteins during preparation of challenge material (OFC with vegetables for example), of a “matrix effect”, of the association with facilitating factors ( food-dependent exercise-induced anaphylaxis, treatment with anti-ulcer medication for example), or other unexplained causes (49,75, 82-84). Further, DBPCFC is considered as the gold standard for the diagnosis of FA. However, events with placebo may occur. Refuting “false positive” challenges may justify repeated challenges in selected cases (85).

The time between last intake and the appearance of symptoms distinguishes between immediate reactions, which occur within two hours (rarely within four hours), delayed reactions and combined reactions (86). Immediate reactions are most frequent. They may be isolated or associated (5, 23, 87 - 89).

### V.2 Signs of reactivity

Symptoms may be cutaneous/mucous, gastrointestinal, respiratory or systemic (Tab. 3) (87, 88). They may also be described as subjective or objective. All signs should be carefully noted on a monitoring form, specifying their time of occurrence and the trigger dose.

*Cutaneous signs* are the most frequent. Subjects may display rashes, urticaria or angio-oedema (22, 88, 89). These symptoms should be quantified in terms of the percentage of the skin area affected. Eczemateous reactions should be scored using an eczema score established at the start of the OFC and a score established at least 24 hours after OFC. For the SCORAD, a difference of at least 10 points is usually considered to indicate a positive reaction (89). Isolated pruritus is usually considered a subjective sign, unless generalised, extensive or observed in certain areas (the extremities).

*Gastrointestinal signs* are also frequent: oral allergy syndrome, crampy abdominal pain, nausea, repeated vomit-

**Table 3** - Classification of symptoms observed during an OFC

Symptoms	Subjective symptoms	Objective symptoms
Cutaneous	Isolated or localised	Pruritus With behavioural evidence of pruritus (e.g. generalised with persistent scratching)
		Erythema Maculo-papular rash Urticaria Angio-oedema Eczema
Gastrointestinal	Isolated pruritus: labial, oral, velo-palantine, pharyngeal Oral allergy syndrome Dysphagia	Enanthema Oedema of the uvula
	Isolated	Abdominal pain With behavioural evidence of abdominal pain (e.g. refusing to move, abdominal pain repeated or associated)
	Nausea	Repeated vomiting Diarrhoea
Respiratory	<i>Nasal/conjunctival:</i>	Nasal congestion Repeated sneezing, Aqueous rhinorrhoea, Rhinoconjunctivitis <i>Laryngeal:</i> Vocal changes Stridor
	<i>Chest:</i> Shortness of breath Chest tightness	Laryngospasm Laryngeal dyspnoea <i>Chest:</i> Cough, wheezing, Dyspnoea Asthma attack Decrease in FEV <sub>1</sub> >15% Decrease in peak flow >20%
General	Tiredness, Changes in behaviour, Prostration, Headaches, Apprehension, refusal to take the next dose	Abnormal pallor Increase in pulse >20% Decrease in blood pressure >20 mmHg Decrease in SaO <sub>2</sub> Collapse Anaphylaxis

ing, diarrhoea (22, 88). Abdominal pain may be a precursor of other signs. Diarrhoea may occur rapidly, or some

time after the occurrence of abdominal pain and may be acute (protein-losing enteropathy) or chronic

(eosinophilic gastroenteropathy). Following the reintroduction of the food into the daily diet, objective signs of malabsorption may constitute evidence in favour of FA (33).

*Respiratory signs* may concern the upper or lower airways: rhinitis, rhinoconjunctivitis, cough, wheeze/bronchospasm, dyspnea (24, 88). Such signs also include changes in the variables monitored (decrease of at least 20% in peak flow, decrease of at least 15% in FEV<sub>1</sub> or decrease in oxygen saturation). Isolated asthma attacks are rare (90).

*Systemic reactions* rarely occur during OFCs (88). Compliance with good practice and the respect of contraindications limit the most severe reactions. Severe reactions may occur with any type of food. Anaphylaxis is a severe, life-threatening, systemic syndrome involving cardiorespiratory symptoms and/or signs such as stridor, wheeze and/or hypotension (3, 4). In the absence of specific treatment, the reaction may progress rapidly, with increasingly severe respiratory and cardiovascular symptoms. Based on the observation that the involvement of skin and other systems, such as the gastrointestinal tract, is generally present initially and may predict the progression of a reaction, a working clinical definition of anaphylaxis has now been proposed by a North American task force and the EAACI (3, 4).

## VI. What are the consequences of an OFC?

Whatever the result obtained in the OFC, this test has an effect on diet and, more generally, on the daily life of the child.

### VI.1 In cases of a negative OFC

If a negative OFC result is obtained, the food can be reintroduced, in the form tested, into the daily diet of the child (4, 24, 33) (grade 1B). However, it is important to ensure that the quantity tolerated by the child on the day of the test corresponds to the amount the child is likely to eat during a normal meal. There is a risk of recurrence, as reported for egg and peanut (55, 91). It would therefore appear sensible to recommend regular consumption of the food in the form tested and tolerated on the day of the OFC (60) (grade 2B). At least during the first few months after the OFC, and regardless of the food concerned, we advise the maintenance of an emergency kit (55) (grade 2C).

### VI.2 In cases of a positive OFC

Continuation of the avoidance diet is recommended; together with food education measures and the prevention of any deficiencies likely to be caused by the diet (33) (grade 1B). These objectives often lead to the intervention of a dietician. The maintenance of an emergency kit is recommended in cases of positive OFC (51) (grade 1B). Its composition may be changed, particularly as concerns the need for adrenaline, according to the reaction observed, the trigger dose, allergic background and the allergen concerned (92,93) (grade 2B). A written action plan should be produced and educational measures should be targeted at the patients and their families (67, 85, 92-95) (grade 1B).

In cases in which the food allergy is likely to resolve over time, the patient should undergo clinical follow-up, with control prick tests and specific IgE determinations to define possible indications for a new OFC. OFC remains indispensable for confirmation of the development of tolerance (23, 58, 64) (grade 1C).

## VII. Conclusion

This practice parameter for OFC in children with FA is an updated review based on an evidence-based approach. It aims to provide guidelines and support for physicians and to improve the quality of care received by children with FA. However, for several items, data remain conflicting, sparse or entirely absent. The recommendations for these items correspond to a consensus statement from the working group experts.

Several questions remain unanswered:

How sensitisation to a food the child does consumes without signs of allergy change over time?

What is the natural history of sensitisation and allergy to the nuts of other trees in a child with confirmed peanut allergy?

What is the natural history of non-IgE-based FA?

For these items, cohort studies, with follow-up from childhood to adulthood are required. The development of new methods should lead to progress in diagnostic work-up and provide information about the allergy and its natural history.

Several questions concerning OFCs also remain unanswered:

Why do false-positive or false-negative OFCs occurred?  
 Can an OFC lead to tolerance induction?  
 Which procedure is the most appropriate for evaluating non-IgE features, particularly as concerns gastrointestinal hypersensitivity to the food?  
 Should the procedure for food tolerance evaluation differ from that for diagnosis?  
 What are the specific indications for low-dose OFC?  
 What conclusions should be drawn about an incomplete OFC without reaction?  
 How does the patient consume the food in the real life after a negative OFC?  
 Further studies and evaluations are required to answer these questions. The proposed practice parameter is subject to subsequent changes and updates, taking into account advances in our knowledge concerning FA diagnosis and OFCs.

## References

- Rancé F, Grandmottet X, Grandjean H. Prevalence and main characteristics of schoolchildren diagnosed with food allergies in France. *Clin Exp Allergy* 2005; 35: 167-72.
- Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: A meta-analysis. *J Allergy Clin Immunol* 2007; 120: 638-46.
- Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *J Allergy Clin Immunol* 2006; 117: 391-7.
- Muraro A, Roberts G, Clark A, et al, EAACI Task Force on Anaphylaxis in Children. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. *Allergy* 2007; 62: 857-71.
- Sampson HA. Update on food allergy. *J Allergy Clin Immunol* 2004; 113: 805-19.
- Primeau MN, Kagan R, Joseph L, et al. The psychological burden of peanut allergy as perceived by adults with peanut allergy and the parents of peanut-allergic children. *Clin Exp Allergy* 2000; 30: 1135-43.
- Sicherer SH, Noone SA, Munoz-Furlong A. The impact of childhood food allergy on quality of life. *Ann Allergy Asthma Immunol* 2001; 87: 461-4.
- Host A, Andrae S, Charkin S, et al. Allergy testing in children: why, who, when and how? *Allergy* 2003; 58: 559-69.
- Sampson HA, Ho DG. Relationship between food-specific IgE concentrations and the risk of positive food challenges in children and adolescents. *J Allergy Clin Immunol* 1997; 100: 444-51.
- Sporik R, Hill DJ, Hosking S. Specificity of allergen skin testing in predicting positive open food challenges to milk, egg and peanut in children. *Clin Exp Allergy* 2000; 30: 1540-6.
- Garcia-Ara C, Boyano-Martinez T, Diaz-Pena JM, Martin-Munoz F, Reche-Frutos M, Martin-Esteban M. Specific IgE levels in the diagnosis of immediate hypersensitivity to cows' milk protein in the infant. *J Allergy Clin Immunol* 2001; 107: 185-90.
- Roehr CC, Reibel S, Ziegert M, Sommerfeld C, Wahn U, Niggemann B. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis. *J Allergy Clin Immunol* 2001; 107: 548-53.
- Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. *J Allergy Clin Immunol* 2001; 107: 891-6.
- Rancé F, Fargeot-Espaliat A, Rittie J, Micheau P, Morelle K, Abbal M. Valeur diagnostique du dosage des IgE spécifiques dirigées contre le blanc d'oeuf et le jaune d'oeuf dans le diagnostic de l'allergie alimentaire à l'oeuf de poule chez l'enfant. *Rev Fr Allergol Immunol Clin* 2003; 43: 369-72.
- Hill DJ, Heine RG, Hosking CS. The diagnostic value of skin prick testing in children with food allergy. *Pediatr Allergy Immunol* 2004; 15: 435-41.
- Verstege A, Mehl A, Rolinck-Werninghaus C, et al. The predictive value of the skin prick test weal size for the outcome of oral food challenges. *Clin Exp Allergy* 2005; 35: 1220-6.
- Celik-Bilgili S, Mehl A, Verstege A, et al. The predictive value of specific immunoglobulin E levels in serum for the outcome of oral food challenges. *Clin Exp Allergy* 2005; 35: 268-73.
- Mehl A, Rolinck-Werninghaus C, Staden U, et al. The atopy patch test in the diagnostic workup of suspected food-related symptoms in children. *J Allergy Clin Immunol* 2006; 118: 923-9.
- Eigenmann PA. Are specific immunoglobulin E titres reliable for prediction of food allergy? *Clin Exp Allergy* 2005; 35: 247-9.
- Niggemann B, Wahn U, Sampson H. Proposals for standardization of oral food challenge tests in infants and children. *Pediatr Allergy Immunol* 1994; 5: 11-3.
- Sicherer SH. Food allergy: when and how to perform oral food challenges. *Pediatr Allergy Immunol* 1999; 10: 226-34.
- Taylor S, Hefle S, Bindslev-Jensen C, et al. A consensus protocol for the determination of the threshold doses for allergenic foods: how much is too much? *Clin Exp Allergy* 2004; 34: 689-95.
- Niggemann B, Rolinck-Werninghaus C, Mehl A, Binder C, Ziegert M, Beyer K. Controlled oral food challenges in children - when indicated, when superfluous? *Allergy* 2005; 60: 865-70.
- Bindslev-Jensen C, Ballmer-Weber BK, Bengtsson U, et al. Standardization of food challenges in patients with immediate reactions to foods-position paper from the European Academy of Allergology and Clinical Immunology. *Allergy* 2004; 59: 690-7.
- Werfel T, Ballmer-Weber B, Eigenmann PA, Niggemann B, Rance F, Turjanmaa K, Worm M. Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN. *Allergy* 2007; 62: 723-8.
- Rancé F, Deschildre A. Test de provocation par voie orale aux aliments chez l'enfant. Quand, pour qui et comment? Introduction, définitions, lexique. *Rev Fr Allergol Immunol Clin* 2006; 46: 604-9.
- Villart-Truc F, Gomez S-A, Deschildre A, Rancé F. Test de provocation par voie orale aux aliments chez l'enfant. Quand, pour qui et comment? Sélection des patients. *Rev Fr Allergol Immunol Clin* 2006; 46: 610-624.
- Santos C, Deschildre A, Paty E, Couderc L, Marguet C, Rancé

- F. Test de provocation par voie orale aux aliments chez l'enfant. Quand, pour qui et comment? Réalisation. *Rev Fr Allergol Immunol Clin* 2006; 46: 659-69.
29. Fauquert JL, Deschildre A, Sabouraud D, Rancé F. Test de provocation par voie orale aux aliments chez l'enfant. Quand, pour qui et comment? Interprétation. *Rev Fr Allergol Immunol Clin* 2006; 46: 670-4.
  30. Deschildre A, Rancé F, Santos C, Castelain C. Test de provocation par voie orale aux aliments chez l'enfant. Quand, pour qui et comment ? Conséquences. *Rev Fr Allergol Immunol Clin* 2006; 46: 675-9.
  31. Rancé F, Deschildre A. Test de provocation par voie orale aux aliments chez l'enfant. Quand, pour qui et comment? Conclusion et points non résolus. *Rev Fr Allergol Immunol Clin* 2006; 46: 680-2.
  32. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence and in clinical guidelines: report from an American College of Chest Physicians Task Force. *Chest* 2006; 129: 174-81.
  33. Sicherer SH, Bock A. An expanding evidence base provides food for thought to avoid indigestion in managing difficult dilemmas in food allergy. *J Allergy Clin Immunol* 2006; 117: 1419-22.
  34. Wainstein BK, Yee A, Jelley D, Ziegler M, Ziegler JB. Combining skin prick, immediate skin application and specific-IgE testing in the diagnosis of peanut allergy in children. *Pediatr Allergy Immunol* 2007; 18: 231-9.
  35. Dreborg S, Foucard T. Allergy to apple, carrot and potato in children with birch pollen allergy. *Allergy* 1983; 38: 167-72.
  36. Ortolani C, Ispano M, Pastorello EA, Ansaloni R, Magri GC. Comparison of results of skin prick tests (with fresh foods and commercial food extracts) and RASTS in 100 patients with oral allergy syndrome. *J Allergy Clin Immunol* 1989; 83: 683-90.
  37. Rancé F, Juchet A, Bremont F, Dutau G. Correlations between skin prick tests using commercial extracts and fresh foods, specific IgE, and food challenges. *Allergy* 1997; 52: 1031-5.
  38. Clark AT, Ewan PW. Interpretation of tests for nut allergy in one thousand patients, in relation to allergy or tolerance. *Clin Exp Allergy* 2003; 33: 1041-5.
  39. Roberts G, Lack G. Diagnosing peanut allergy with skin prick and specific IgE testing. *J Allergy Clin Immunol* 2005; 115: 1291-6.
  40. Niggemann B, Reibel S, Roehr CC, et al. Predictors of positive food challenge outcome in non-IgE-mediated reactions to food in children with atopic dermatitis. *J Allergy Clin Immunol* 2001; 108: 1053-8.
  4. Fogg MI, Brown-Whitehorn TA, Pawlowski NA, Spergel JM. Atopy patch test for the diagnosis of food protein-induced enterocolitis syndrome. *Pediatr Allergy Immunol* 2006; 17: 351-5.
  42. Canani RB, Ruotolo S, Auricchio L, et al. Diagnostic accuracy of the atopy patch test in children with food allergy-related gastrointestinal symptoms. *Allergy* 2007; 62: 738-43.
  43. Société Française de Dermatologie. Prise en charge de la dermatite atopique de l'enfant. Texte court. *Ann Dermatol Venerol* 2005; 132: 81-91.
  44. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). *J Allergy Clin Immunol* 2004; 113: 11-28.
  45. Kalach N, Soulaïnes P, de Boissieu D, Dupont C. A pilot study of the usefulness and safety of a ready-to-use atopy patch test (Diallertest) versus a comparator (Finn Chamber) during cow's milk allergy in children. *J Allergy Clin Immunol* 2005; 116: 1321-6.
  46. Heine RG, Verstege A, Mehl A, Staden U, Rolinck-Werninghaus C, Niggemann B. Proposal for a standardized interpretation of the atopy patch test in children with atopic dermatitis and suspected food allergy. *Pediatr Allergy Immunol* 2006; 17: 213-7.
  47. Turjanmaa K, Darsow U, Niggemann B, Rancé F, Vanto T, Werfel T. Present status of the Atopy Patch Test. Position Paper of the Section on Dermatology and the Section on Pediatrics of the European Academy of Allergy and Clinical Immunology (EAACI) and GA<sup>2</sup>LEN. *Allergy* 2006; 61: 1377-84.
  48. van Odijk J, Ahlstedt S, Bengtsson U, Borres MP, Hulthen L. Double-blind placebo-controlled challenges for peanut allergy the efficiency of blinding procedures and the allergenic activity of peanut availability in the recipes. *Allergy* 2005; 60: 602-5.
  49. Grimshaw KE, King RM, Nordlee JA, Hefle SL, Warner JO, Hourihane JO. Presentation of allergen in different food preparations affects the nature of the allergic reaction - a case series. *Clin Exp Allergy* 2003; 33: 1581-5.
  50. Taylor S, Hefle S, Bindslev-Jensen C, et al. Factors affecting the determination of threshold doses for allergenic foods: how much is too much? *J Allergy Clin Immunol* 2002; 109: 24-30.
  51. Hourihane JO, Grimshaw KE, Lewis SA, et al. Does severity of low-dose, double-blind, placebo-controlled food challenges reflect severity of allergic reactions to peanut in the community? *Clin Exp Allergy* 2005; 35: 1227-33.
  52. Hourihane JO, Roberts SA, Warner JO. Resolution of peanut allergy: case-control study. *BMJ* 1998; 316: 1271-5.
  53. Vander LT, Liu A, Stefanski K, Blacker B, Bock S. The natural history of peanut allergy in young children and its association with serum peanut-specific IgE. *J Pediatr* 2000; 137: 749-55.
  54. Wood RA. The natural history of food allergy. *Pediatrics* 2003; 111: 1631-7.
  55. Fleischer DM, Conover-Walker MK, Christie L, Burks AW, Wood RA. Peanut allergy: recurrence and its management. *J Allergy Clin Immunol* 2004; 114: 1195-201.
  56. Saarinen KM, Pelkonen AS, Makela MJ, Savilahti E. Clinical course and prognosis of cow's milk allergy are dependent on milk-specific IgE status. *J Allergy Clin Immunol* 2005; 116: 869-75.
  57. Boyano-Martinez T, Garcia-Ara C, Diaz-Pena JM, Martin-Esteban M. Prediction of tolerance on the basis of quantification of egg white-specific IgE antibodies in children with egg allergy. *J Allergy Clin Immunol* 2002; 110: 304-9.
  58. Thong B, Hourihane J. Monitoring of IgE-mediated food allergy in childhood. *Acta Paediatr* 2004; 93 : 759-64.
  59. Niggemann B, Celik-Bilgili S, Ziegert M, Reibel S, Sommerfeld C, Wahn U. Specific IgE levels do not indicate persistence or transience of food allergy in children with atopic dermatitis. *J Invest Allergol Clin Immunol* 2004; 14: 98-103.
  60. Eigenmann PA, Caubet JC, Zamora SA. Continuing food-avoidance diets after negative food challenges. *Pediatr Allergy Immunol* 2006; 17: 601-5.
  61. Knight AK, Shreffler WG, Sampson HA, et al. Skin prick test to egg white provides additional diagnostic utility to serum egg

- white-specific IgE antibody concentration in children. *J Allergy Clin Immunol* 2006; 117: 842-7.
62. Nolan RC, Richmond P, Prescott SL, et al. Skin prick testing predicts peanut challenge outcome in previously allergic or sensitized children with low serum peanut-specific IgE antibody concentration. *Pediatr Allergy Immunol* 2007; 18: 224-30.
63. Shek LP, Soderstrom L, Ahlstedt S, Beyer K, Sampson HA. Determination of food specific IgE levels over time can predict the development of tolerance in cow's milk and hen's egg allergy. *J Allergy Clin Immunol* 2004; 114: 387-91.
64. Perry T, Matsui E, Kay C-WM, Wood R. The relationship of allergen-specific IgE levels and oral food challenge outcome. *J Allergy Clin Immunol* 2004; 114: 144-9.
65. Vanto T, Helpilla S, Juntunen-Backman K, et al. Prediction of the development of tolerance to milk in children with cow's milk hypersensitivity. *J Pediatr* 2004; 144: 218-22.
65. Sicherer SH, Sampson HA. 9. Food allergy. *J Allergy Clin Immunol* 2006; 117: S470-5.
66. Osterballe M, Bindslev-Jensen C. Threshold levels in food challenge and specific IgE in patients with egg allergy: is there a relationship? *J Allergy Clin Immunol* 2003; 112: 196-201.
67. Lieberman P, Kemp F, Oppenheimer J, Lang DM, Berstein L, Nicklas A and the task force on practice parameters. The diagnosis and management of anaphylaxis: an updated practice parameter. *J Allergy Clin Immunol* 2005; 115: S483-S523.
68. Eigenmann PA. Anaphylactic reactions to raw eggs after negative challenges with cooked eggs. *J Allergy Clin Immunol* 2000; 105: 587-8.
69. Vlieg-Boerstra B, Bijleveld C, van der Heide S, et al. Development and validation of challenge materials for double-blind, placebo-controlled food challenges in children. *J Allergy Clin Immunol* 2004; 113: 341-6.
70. Noe D, Bartemucci L, Mariani N, Cantari D. Practical aspects of preparation of foods for double-blind, placebo-controlled food challenge. *Allergy* 1998; 53: 75-7.
71. Niggemann B. Role of oral food challenges in the diagnostic work-up of food allergy in atopic eczema dermatitis syndrome. *Allergy* 2004; 59 Suppl 78: 32-4.
72. Bock SA. Diagnostic evaluation. *Pediatrics* 2003; 111: 1638-44.
73. Reibel S, Rohr C, Ziegert M, Sommerfeld C, Wahn U, Niggemann B. What safety measures need to be taken in oral food challenges in children? *Allergy* 2000; 55: 940-4.
74. Bock SA, Sampson HA, Atkins FM, et al. Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual. *J Allergy Clin Immunol* 1988; 82: 986-97.
75. Caffarelli C, Petroccione T. False-negative food challenges in children with suspected food allergy. *Lancet* 2001; 358: 1871-2.
76. Hourihane JB, Kilburn SA, Nordlee JA, Hefle SL, Taylor SL, Warner JO. An evaluation of the sensitivity of subjects with peanut allergy to very low doses of peanut protein: a randomized, double-blind, placebo-controlled food challenge study. *J Allergy Clin Immunol* 1997; 100: 596-600.
77. Simons FE. Anaphylaxis, killer allergy: long-term management in the community. *J Allergy Clin Immunol* 2006; 117: 117: 367-77.
78. Simons F. Advances in H1-antihistamines. *N Engl J Med* 2004; 351: 2203-17.
79. Sheikh A, ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis with and without shock. *Cochrane Database Syst Rev* 2007;(1):CD006160.
80. Global initiative for asthma. <http://www.ginasthma.com/>
81. Marguet C, pour le GRAPP (Groupe de Recherche sur les Avancées en Pneumologie Pédiatrique). Traitement de la crise d'asthme de l'enfant. *Rev Mal Respir* 2007; 24: 427-39.
82. Skamstrup Hansen K, Vestergaard H, Stahl Skov P, et al. Double-blind, placebo-controlled food challenge with apple. *Allergy* 2001; 56 (2): 109-17.
83. Aihara M, Miyazawa M, Osuna H, et al. Food-dependent exercise-induced anaphylaxis: influence of concurrent aspirin administration on skin testing and provocation. *Br J Dermatol* 2002; 146: 466-72.
84. Untersmayr E, Jensen-Jarolim E. The role of protein digestibility and antacids on food allergy outcomes. *J Allergy Clin Immunol* 2008; 121: 1301-8.
85. Vlieg-Boerstra BJ, van der Heide S, Bijleveld CM, Kukler J, Duiverman EJ, Dubois AE. Placebo reactions in double-blind, placebo-controlled food challenges in children. *Allergy* 2007; 62: 905-12.
86. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. *J Allergy Clin Immunol* 2004; 113: 832-6.
87. Bock SA, Atkins FM. Patterns of food hypersensitivity during sixteen years of double-blind, placebo-controlled food challenges. *J Pediatr* 1990; 117: 561-7.
88. Perry TT, Matsui EC, Conover-Walker MK, Wood RA. Risk of oral food challenges. *J Allergy Clin Immunol* 2004; 114: 1164-8.
89. Breuer K, Heratizadeh A, Wulf A, et al. Late eczematous reactions to food in children with atopic dermatitis. *Clin Exp Allergy* 2004; 34: 817-24.
90. James JM, Eigenmann PA, Eggleston PA, Sampson HA. Airway reactivity changes in asthmatic patients undergoing blinded food challenges. *Am J Respir Crit Care Med* 1996; 153: 597-603.
91. Busse PJ, Nowak-Wegrzyn AH, Noone SA, Sampson HA, Sicherer SH. Recurrent peanut allergy. *N Engl J Med* 2002; 347: 1535-6.
92. Didier A. Conditions d'établissement d'un projet d'accueil individualisé en cas de risque d'urgences allergiques alimentaires. *Commission tripartite. Rev fr Allergol* 2003; 43: 415-18.
93. Ewan PW, Clark AT. Efficacy of a management plan based on severity assessment in longitudinal and case-controlled studies of 747 children with nut allergy: proposal for good practice. *Clin Exp Allergy* 2005; 35: 751-6.
94. Kapoor S, Roberts G, Bynoe Y, Gaughan M, Habibi P, Lack G. Influence of a multidisciplinary paediatric allergy clinic on parental knowledge and rate of subsequent allergic reactions. *Allergy* 2004; 59: 185-91.
95. Munoz-Furlong A. Daily coping strategies for patients and their families. *Pediatrics* 2003; 111: 1654-61.